COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Journey™ UNI Post Market Clinical Follow-Up (Journey UNI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03442231
Recruitment Status : Enrolling by invitation
First Posted : February 22, 2018
Last Update Posted : March 13, 2020
Information provided by (Responsible Party):
Smith & Nephew, Inc.

Brief Summary:
This is a retrospective/prospective, open-label single cohort, multicenter study to collect relevant clinical data from 147 subjects with unicompartmental degeneration of the knee in whom the Journey UNI UKS was previously implanted.

Condition or disease Intervention/treatment
Non-inflammatory Degenerative Joint Disease Device: Journey UNI Unicompartmental Knee System

Detailed Description:
The purpose of the current investigation is to assess the safety and effectiveness of the JOURNEY UNI Unicompartmental Knee System (UKS) in patients with non-inflammatory degenerative joint disease (NIDJD) of the knee who previously had the Journey UNI UKS implanted. This clinical study will prospectively evaluate the 36 and 60-month safety and performance of the JOURNEY UNI UKS in patients with NIDJD of the knee who required lateral or medial knee compartment replacement.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 147 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Follow-Up of Subjects With a Journey™ UNI Unicompartmental Knee System Implant
Actual Study Start Date : April 11, 2018
Estimated Primary Completion Date : April 11, 2025
Estimated Study Completion Date : April 11, 2025

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Journey™ UNI Unicompartmental Knee System
Subjects previously received knee replacement
Device: Journey UNI Unicompartmental Knee System
Lateral or medial knee compartment replacement

Primary Outcome Measures :
  1. Implant survival rate [ Time Frame: 5 years ]
    Did knee survive with no revision through 5 years

Secondary Outcome Measures :
  1. Quality of Life - KSS [ Time Frame: 5 Years ]
    2011 Knee Society Score

  2. Quality of Life - EQ-5D - 3L [ Time Frame: 5 Years ]
    EuroQol Five Dimensions Questionnaire

  3. Quality of Life - SAPSS [ Time Frame: 5 Years ]
    Self-Administered Patient Satisfaction Survey

  4. Quality of Life - Forgotten Joint Score [ Time Frame: 5 Years ]
    Forgotten Joint Score (FJS) questionnaire measures how often subject is aware of affected knee in everyday life. Score consists of 12 questions where subjects are asked to rate their awareness of their joint replacement during various activities. rating is never, almost never, seldom, sometimes or mostly.

  5. Adverse Events (AEs) [ Time Frame: 5 Years ]
    All AEs will be collected and reported

  6. Radiographic Outcomes [ Time Frame: 5 Years ]
    Perform weight-bearing AP and lateral standard x-rays

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Investigators will pre-screen all subjects that have previously undergone UKA using the Journey UNI UKS system between 12 and 48 months previously using only the existing information in the medical records.

Inclusion Criteria:

  1. Between 12 and 48 months previously, subject had unicompartmental knee replacement implanted for unicompartmental, NIDJD including OA, traumatic arthritis, avascular necrosis, for correction of functional deformity, or to repair a fracture that was unmanageable using other techniques.
  2. Subject received a Journey UKS implant (consisting of a femoral component, tibial baseplate, and a tibial insert).
  3. Subject was considered skeletally mature at the time of surgery and was at least 18 years of age.
  4. Subject is willing to have retrospective data collected and to participate in required prospective follow-up visit(s) at the investigational site and to complete study procedures and questionnaires.
  5. Subject has consented to participate in the study by signing the Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form (ICF).

Exclusion Criteria:

  1. Subject has Body Mass Index (BMI) > 40 within 1 month of surgery.
  2. Subjects who have received the Journey UNI UKS as part of a revision surgery.
  3. Subject has a condition that may interfere with the unicompartmental knee arthroplasty (UKA) survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
  4. Subject has a known allergy to study device or one or more of its components.
  5. Subject, in the opinion of the Principal Investigator (PI), has an emotional or neurological condition that would preempt his/her ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
  6. Subject is entered in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days.
  7. Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03442231

Layout table for location information
United States, Arizona
Orthopaedic Specialists of Central Arizona-Scottsdale
Scottsdale, Arizona, United States, 85255
United States, Illinois
Orthopaedic Surgery Specialists, Ltd.
Park Ridge, Illinois, United States, 60068
United States, Tennessee
Tennesee Orthopaedic Alliance, P.A.
Nashville, Tennessee, United States, 37209
Canada, Ontario
London Health Sciences Centre-University Hospital
London, Ontario, Canada, N6A5A5
Sponsors and Collaborators
Smith & Nephew, Inc.
Layout table for investigator information
Study Chair: Salima Reddy Smith & Nephew, Inc.

Layout table for additonal information
Responsible Party: Smith & Nephew, Inc. Identifier: NCT03442231    
Other Study ID Numbers: 17-4049-03
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: March 13, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Smith & Nephew, Inc.:
traumatic arthritis
avascular necrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases